Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BMW sets aside £207m for motor finance redress as FCA pressure mounts

(Sharecast News) - Car finance firm BMW Financial Services has set aside £206.9m to cover potential compensation linked to the UK motor finance mis-selling scandal, according to accounts filed at Companies House. The provision, up from £70.3m a year earlier, reflects mounting pressure on lenders ahead of a proposed redress scheme from the Financial Conduct Authority, which has been consulting on industry-wide compensation for consumers who may have been mis-sold car loans between 2007 and 2020, particularly under discretionary commission arrangements that incentivised dealers to charge higher interest rates - a practice that was banned in 2021.

BMW said the provision covers expected payouts, legal costs and administrative expenses, but warned of "considerable uncertainty" around the final scale of claims. A 5% increase in expected payouts could add a further £31m to the total, it noted. The FCA has estimated that total industry liabilities could reach between £9bn and £18bn, drawing comparisons with the payment protection insurance scandal.

BMW joins a growing list of lenders preparing for significant financial impact, including Lloyds Banking Group, Santander UK and Close Brothers.

Although a Supreme Court ruling in July largely favoured lenders, the FCA has signalled its intention to press ahead with compensation, with chief executive Nikhil Rathi telling MPs that he expects a "critical mass" of complaints to be resolved by 2026.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.